Abstract Vascular endothelial growth factor (VEGF) expression is higher in triple-negative breast cancers (TNBC) compared to other subtypes and is reported to predict incidence of distant metastases and shorter overall survival. We investigated the therapeutic impact of a vaccinia virus (VACV) GLV-1h164 (derived from its parent virus GLV-1h100), encoding a single-chain antibody (scAb) against VEGF (GLAF-2) in an orthotopic TNBC murine model. GLV-1h164 was tested against multiple TNBC cell lines. Viral infectivity, cytotoxicity, and replication were determined. Mammary fat pad tumors were generated in athymic nude mice using MDA-MB-231 cells. Xenografts were treated with GLV-1h164, GLV-1h100, or PBS and followed for tumor growth. Viral infectivity was time-and concentration-dependent. GLV-1h164 killed TNBC cell lines in a dose-dependent fashion with greater than 90 % cytotoxicity within 4 days at a multiplicity of infection of 5.0. In vitro, cytotoxicity of GLV-1h164 was identical to GLV-1h100. GLV-1h164 replicated efficiently in all cell lines with an over 400-fold increase in copy numbers from the initial viral dose within 4 days. In vivo, mean tumor volumes after 2 weeks of treatment were 73, 191, and 422 mm 3 (GLV-1h164, GLV-1h100, and PBS, respectively) (p \ 0.05). Both in vivo Doppler ultrasonography and immuno-staining showed decreased neoangiogenesis in GLV-1h164-treated tumors compared to both GLV-1h100 and PBS controls (p \ 0.05). This is the first study to demonstrate efficient combination of oncolytic and anti-angiogenic activity of a novel VACV on Sepideh Gholami and Andrew Marano have contributed equally to this work.
Introduction
Triple-negative breast cancer (TNBC) is a particularly aggressive subtype of breast cancer for which there are currently no effective forms of targeted therapy. The hallmark of TNBCs is their lack of expression of estrogen and progesterone receptors, as well as the lack of overexpression of the human epidermal growth factor 2 (Her2) receptor. This lack of expression precludes use of a number of therapeutic agents commonly used to treat other hormone and EGFR-expressing forms of breast cancer [1] . Additionally, TNBCs are associated with high rates of recurrence and carry a poor prognosis; patients with TNBC have a reduced overall survival [2, 3] . This form of disease is more common in younger African-American and Hispanic women and constitutes approximately 15 % of all breast cancers [1, 3] . TNBCs represent a highly proliferative form of malignancy and depend on stimulation of new blood vessel growth. Studies have shown that vascular endothelial growth factor (VEGF) content of human TNBC tumors was three times higher compared with other subtypes [4] . VEGF is a mediator of angiogenesis and has thus become a target for TNBC therapy. Previous studies have shown the importance of angiogenesis to tumor growth and the effectiveness of anti-angiogenic agents. Bevacizumab, an agent that targets the VEGF pathway, has been shown to significantly improve progression-free survival and objective response rate in human trials in breast cancer when administered in combination with other cancer therapy drugs [5] . Other researchers have demonstrated that ellagic acid, another anti-angiogenic agent, significantly inhibits cancer growth in TNBCs specifically [6] . Novel antiangiogenic agents have notable biologic activity in the treatment of TNBC and merit further investigation.
In our laboratory, we have previously shown that vaccinia virus (VACV) can infect, replicate in, and kill cancer cells, including anaplastic thyroid [7] , pancreatic [8] , glioma [9] , and breast [10] , specifically including TNBC [11] . GLV1h164 is an oncolytic VACV strain that contains the singlechain antibody (scAb) sequence for GLAF-2, an antibody directed against VEGF. Previous research has shown that GLAF is highly expressed in pancreatic cells infected with anti-VEGF vaccinia constructs and that it possesses significant inhibitory effects on the development of blood vessels [12] . Moreover, this viral construct has demonstrated significantly improved tumor therapy in xenografts compared to the parent virus. The success of both anti-angiogenic agents and the oncolytic VACV in treating cancer has led us to the objective of this study: to investigate the therapeutic efficacy of this novel vaccinia strain in TNBC cell lines and our established TNBC mammary fat pad xenograft model.
Materials and methods

Cell lines
Human TNBC cell lines MDA-MB-468, HCC-1143, HCC-1806, and African green monkey kidney fibroblasts (CV-1) were obtained from American Type Culture Collection (American Type Culture Collection, Manassas, VA USA). Human MDA-MB-231 breast carcinoma cells stably expressing mCherry fluorescent protein (kindly provided by Dr. Koblinski from Northwestern University) were maintained in Dulbecco's modified Eagle's medium (DMEM)/F12 supplemented with 5 % FBS, 100 IU/ml penicillin/streptomycin, 1 mM sodium pyruvate, 29 nonessential amino acids and 1 lg/ml blasticidin (SigmaAldrich, St. Louis, MO, USA). MDA-MB-468 cells were maintained in DMEM supplemented with 5 % FBS, 100 IU/ml penicillin/streptomycin, 1 mM sodium pyruvate, 29 nonessential amino acids. HCC1143 and 1806 cell lines were maintained in RPMI supplemented with 10 mM Hepes, 2 mM L-glutamine, 1 mM sodium pyruvate, 1.5 g/l sodium bicarbonate, and 4.5 g/l glucose. CV-1 cells were maintained in minimum essential medium (MEM). Unless otherwise specified, all media were supplemented with 10 % FCS and penicillin (100,000 U/l) and streptomycin (100 mg/l), and cells were grown in a 5 % CO 2 -humidified incubator at 37°C.
Generation of GLV-1h100 and GLV-1h164
The plasmid 0608997-pGA4 [12] was used as a template to amplify GLAF-2 scAb from the GLAF-1 scAb sequence with the primers G6-for-b (5 0 -GTCGACCCACCATGGAG AC-3 0 ) and G6-rev-b (5 0 -TTAATTAATTATCGCTTAAT CTCAACCTTGGTCCC-3 0 ) thereby deleting the DDDDK tag. The sequence GLAF-2 was subcloned into pCRII-TOPO (Invitrogen). The GLAF-2 fragment was cloned into the framework plasmid via the SalI and PacI sites, yielding the plasmid pHA-PSL-GLAF-2. GLV-1h164 was generated from GLV-1h100 using pHA-PSL-GLAF-2. All recombinant viruses were constructed using the method described previously [13] . The genotype of each recombinant virus was confirmed by PCR and sequencing. Viral constructs are illustrated in Fig. 1a . Fig. 1 Green fluorescent protein expression Cells were plated at 1.5 9 10 4 cells/well in 96-well plates and incubated overnight. Cells were infected with GLV1h164 at multiplicities of infection (MOIs) of 1, 5, and 10. At 1, 2, and 3 days post-infection, pictures were taken with an inverted fluorescence microscope (Nikon Eclipse TE300; Nikon, Tokyo, Japan).
Cytotoxicity assay
Cells were plated at 3 9 10 4 cells/well in 24-well plates and incubated overnight. Cells were then infected with either GLV-1h164 or GLV-1h100 at MOIs of 0.1, 1, and 5, and media were concurrently replaced in the controls. Cells were lysed daily for 5 days after treatment with 1.35 % Triton-X solution to release lactate dehydrogenase (LDH). 
Viral replication assay
Viral replication in TNBCs was quantified using a standard plaque assay. TNBCs were plated at 3 9 10 5 in 6-well flatbottom assay plates in 2 ml of media and incubated at 37°C. Cells were infected with either virus (GLV-1h164 or GLV-1h100) at MOIs 1 and 5, and supernatants were harvested daily for a total of 4 days. Serial dilutions of each sample were used to infect CV-1 cells on confluent 12-well plates, and viral titers were determined by counting viral plaques after 72 h.
GLAF-2 expression
MDA-MB-468 cells were infected with either virus strain at an MOI of 1. At 24 and 48 h post-infection, cell lysates and culture supernatants were collected. Proteins were denatured and analyzed with SDS-PAGE. Twenty microgram protein samples were loaded on 4-20 % Tris-HCl buffered gels using the Bio-rad system (Bio-Rad Laboratories, San Francisco, CA). After electrophoresis, proteins were transferred to a PVDF membrane and blocked in 5 % milk in Tris-buffered saline with Tween-20 (TBST). Membranes were incubated with a (rabbit) antibody against GLAF-2 (Genelux, San Diego, CA) at a concentration of (1:5,000) and incubated overnight at 4°C. After washing with TBS-T, horseradish peroxidase-conjugated goat anti-rabbit IgG (Santa Cruz Biotechnology, Santa Cruz, CA) was applied for 1 h, followed by enhanced chemiluminescence Western blotting detection reagents (Amersham, Arlington Heights, IL).
In vivo tumor therapy
Thirty-three female athymic nude mice (Hsd: athymic Nude-Foxn1 nu ) aged 6-8 weeks were injected with 5 9 10 6 MDA-MB-231 mCherry cells suspended in 50 % matrigel into the mammary fat pad. Two weeks after tumor implantation, mice were sorted randomly into three groups and injected intratumorally with either PBS, GLV-1h100, or GLV-1h164 (1 9 10 6 ). Tumor growth was measured every 3 days over the course of 3 weeks. Tumor volumes were calculated by the equation, V (mm
, where a is the smallest diameter and b the largest diameter. Three weeks after treatment, mice were sacrificed and tumors and organs (lung, kidney, spleen, ovaries, and heart) were harvested and frozen for further immunofluorescence staining, histopathology review, and viral plaque assay.
In vivo viral plaque assay
At the end of treatment in our orthotopic model, three mice each from the treatment and control group were euthanized, and tumors and organs (lung, heart, ovaries, kidney, and spleen) were excised, weighed, inspected, and homogenized in 0.5 ml of PBS-containing proteinase inhibitors using MagNA Lyser (Roche Diagnostics, Indianapolis, IN) at a speed of 6500 rpm for 3 min. After three cycles of freeze and thaw, the supernatants were collected by centrifugation at 1200 rpm for 5 min. The viral titers were determined in duplicate by standard plaque assays on confluent 12-well plates of CV-1 cells.
Doppler ultrasonography
A separate group of animals was treated as mentioned above. After 3 weeks of treatment, animals were imaged by Doppler ultrasound using a dedicated small-animal ultrasound system (Vevo 2100, Visualsonics, Toronto, Canada). To ensure that the tumor size was not a confounding factor, tumors of similar sizes from each treatment group were selected.
Tissue preparation
To prepare tissue sections for HE and IF, tissues were fixed with 4 % paraformaldehyde in PBS overnight at 4°C, washed in 70 % ethanol and processed for paraffin embedding as per the standard protocol of the Molecular Cytology Core Facility of MSKCC. Five micron serial sections were cut from paraffin-embedded tumor tissue blocks. Slides were air dried and baked at 60°C for 1 h. Immunofluorescence and H&E staining were performed to detect the presence of vascular density in treated versus control tumors. H&E slides were reviewed by a breast pathologist at MSKCC.
Immunofluorescence and H&E staining IF was performed with the primary antibodies, rat polyclonal anti-MECA-32 (DSHB, 3 lg/ml) and chicken polyclonal anti-GFP (Abcam, 2 lg/ml) by automated Ventana XT machine. Slides were first blocked with blocking solution (10 % normal goat serum in 2 % BSA in PBS) for 10 min. Primary antibody incubation lasted 6 h at 37°C, followed by 60 min of incubation with biotinylated rabbit anti-rat and biotinylated goat anti-chicken secondary antibodies from ABC Vectastain kit (Vector Laboratories; 7.5 lg/ml). Detection was performed with DABMap kit (Ventana Medical Systems) and Tyramide Signal Amplification Alexa Fluor 488 (Invitrogen TSA kit). Tissue slides were counterstained with DAPI (Sigma-Aldrich, 10 lg/ml) for 10 min at room temperature. IF-stained slides were digitally scanned with Zeiss Mirax Scan with 209/0.8NA objective. Images obtained from the scanner were imported to Metamorph (BioVision) where appropriate threshold values for MECA-32 and DAPI were set. Thresholded area of MECA-32 was normalized to the thresholded area of DAPI. Total of 15 images from three individual sections per treatment group were analyzed. H&E staining of tissue sections were performed per routine protocols and reviewed by a breast pathologist at MSKCC.
Statistical analysis
Results are reported as means with standard errors. Significance of the difference between different groups was calculated using Student's t test. Differences were deemed significant if the p value was less than 0.05.
Results
Viral infection is time-and dose-dependent in vitro
GFP expression was evaluated in four TNBC cell lines at 24, 48, and 72 h post-infection. Expression was visible in all cell lines and increased with time, as evidenced by the increasing number of green cells and intensity of the green signal as time increases in Fig. 1b . Nearly, 100 % of cells expressed GFP by day 3 post-infection. In addition, GFP expression also increased with increasing dose, as seen by the same trend across increasing MOIs in Fig. 1c . With increasing MOI (MOI 10 compared to MOI 1), almost all cells were infected within 48 h post-infection.
Cytotoxicity in human TNBC cell lines is timeand dose-dependent in vitro
All cell lines were sensitive to GLV-1h164 and greater cytotoxicity was measured both at later time points and higher MOIs (Fig. 2a) . Greater than 90 % cell kill was achieved by day 4 at MOI 5 in all TNBC cell lines. Compared to the parent virus, GLV-1h100, there was no significant difference in the cytotoxicity pattern (Fig. 2b) .
GLV-1h164 replicates effectively in all TNBC cell lines in vitro
Four TNBC cell lines were treated with GLV-1h164 or GLV-1h100 at an MOI of 1 and viral replication was measured each day for 4 days post-infection. All cell lines supported replication of both viral constructs and, by day 4, plaque-forming units (PFUs) increased up to 650-fold from the initial viral dose. Furthermore, there was no significant difference in the replication efficiency between the two vaccinia strains (Fig. 3) .
Anti-VEGF scAb protein is expressed in infected MDA-MB-468 cells
Cells were infected with either viral construct at an MOI of 1 and the lysates and culture supernatants were collected at 24-and 48-h time points. Western blot analysis revealed anti-VEGF antibody GLAF-2 expression in GLV-1h164-infected cells and their supernatants, but not in the negative control or parent virus treatment groups. In addition, culture supernatant samples suggested increased expression at the later time point whereas cell lysate samples showed similar expression at both time points (Fig. 4) .
GLV-1h164 causes significant tumor regression in TNBC xenografts
Mice bearing MDA-MB-231 mammary fad pad tumors were treated with either viral construct. Tumors infected with GLV-1h164 demonstrated a significantly larger tumor volume regression compared to both the negative control (p \ 0.05) and the parent virus (GLV-1h100) (p \ 0.05). By day 36, the average tumor size was 414 mm 3 for the control group and 200 mm 3 for the parent virus group (p \ 0.05). The GLV-1h164-treated mice had significantly reduced tumor size compared to both groups with a mean volume of 67 mm 3 (p \ 0.05) (Fig. 5) .
GLV-1h164-infected tumors exhibit decreased vascular flow compared to parent virus-treated and uninfected control groups
Six mice with tumors of similar size, two from each group, were selected and their tumors were imaged with Doppler ultrasonography. Images showed a noticeably decreased vascular flow in tumors treated with GLV-1h164 compared to tumors infected with GLV-1h100 or uninfected controls (Fig. 6 ). Images were taken 3 weeks after infection. 5 Tumor volume of mammary fat pad xenografts in untreated, GLV-1h100, and GLV-1h164 treatment groups in vivo. Tumors were injected with either virus or PBS (control) 2 weeks after tumor formation (D0). Tumor volumes were measured three times a week of cell nuclei in three groups (blue-stained with DAPI), virus in the two infected treatment groups (green-green fluorescence protein), and decreased vasculature in only GLV-1h164 treatment group (red-MECA-32) (Fig. 7a) . The signal intensity of the red fluorescence was quantified and revealed a two-fold decrease in GLV-1h164-infected samples compared to uninfected controls (Fig. 7b) .
GLV-1h164-infected
Discussion
TNBCs are a subset of breast cancers that lack expression of hormone receptors and the overexpression of the Her2/ neu receptor. The lack of these cell surface targets makes this subtype of breast cancer unsusceptible to forms of targeted therapies and creates an unmet need for treatment for these specific tumors. Clinically, TNBCs are characterized by early relapses and metastatic disease, with chemotherapy usually the only therapeutic option for those patients. However, patients with recurrent or metastatic TNBC show a particularly limited duration of response to successive chemotherapy agents [14, 15] .
Our laboratory recently reported promising results using oncolytic vaccinia viral therapy for TNBC [16] . We therefore investigated the therapeutic effect of a novel VACV expressing an anti-VEGF antibody in an orthotopic murine TNBC model. Our data show that GLV-1h164 effectively infects and decreases the growth rate of multiple TNBC cell lines in vitro. Moreover, we demonstrate unaltered replication efficacy of this novel virus. In other words, the insertion of the therapeutic gene cassette into the viral genome did not negatively affect or attenuate the previously demonstrated viral replication potential within TNBC. Lastly, we illustrate that GLV-1h164 achieves significant cytotoxicity against orthotopic mammary fat pad tumors in vivo by causing decreased vascular density, as demonstrated by our Doppler flow studies and immunostaining of tumor tissues 3 weeks after a single dose or viral therapy in addition to direct oncolysis.
Most research studies have focused on key signaling pathways in TNBC to develop new targeted agents. Targeting of the angiogenic factor VEGF has been shown to improve outcomes in human breast cancer patients. The most prominent findings with respect to anti-angiogenic therapy of breast cancer include prolonged progression-free survival in patients with metastatic breast cancer [17] [18] [19] treated with bevacizumab, indicating biologic activity of this agent in this disease. These are encouraging results. While the long-term overall survival data remain fully to be elucidated, progression-free survival and recurrence rates are important outcome metrics for both patients and ongoing research studies to be considered. Moreover, studies of combining multiple therapies have shown improved outcomes with synergistic mechanisms. We therefore hoped to show improved efficacy of a combination drug versus one drug alone in effort to decrease cytotoxicity and cost. It has been well described that angiogenesis is required for tumor growth and progression. With regards to TNBC, high levels of VEGF have been associated with a less favorable treatment prognosis [12] . For bevacizumab, however, the main issue still remains that, like many other targeted therapies, the clinical benefit is modest and is significant only when combined with other therapeutic agents [20] . As these tumors develop resistance to most conventional chemotherapeutic agents relatively quickly [2] , we proposed the use of an oncolytic virus for treatment of TNBC. The rationale for this approach is that the mechanisms of oncolytic viral infection and cell lysis are independent of the molecular pathways that drive tumor initiation and growth; thus, treatment with an oncolytic virus should therefore not be affected by conventional pathways of resistance developed in these breast cancer cells. Our recent results show a similar VACV achieving a significant therapeutic effect in an orthotopic TNBC model. We therefore developed a novel multi-targeted therapeutic agent for TNBC, an oncolytic virus engineered to express an anti-angiogenic antibody in virally-infected cells. This enhancement in therapeutic effect may be caused by the continuous production of the anti-VEGF scAb, which can decrease vascular flow supplying the tumor. Moreover, assessment of microvascular density is becoming more feasible through use of digital micro-imaging and analysis. Increased microvascular density has been associated with higher grade of tumors [21] . As our study demonstrated the efficacy of an anti-angiogenic virus in treatment of TNBC, future work will include examination and measurement of the effects of viral treatment on microvessel density.
Finally, a potential mechanism contributing to the observed enhanced effect of this virus in the current study would potentially be an immunomodulatory effect by the scAb as well as the virus itself. Research has been reported that angiogenic factors including VEGF can decrease the immune response in tumors [22] . In addition, infected breast tumors with VACV have been shown to have an activated innate immune system [23] and potentially cause recruitment of the immune effector cells in the tumor microenvironment [24, 25] . Specifically, whether this novel VACV with over-expression of GLAF-2 scAb has an effect on the immune system needs to be further studied.
An additional advantage of oncolytic viruses is that they can serve as vehicles for therapeutic transgenes and thus offer a non-invasive form of therapeutic monitoring. GLV1h164 has the ability to detect disease to the presence of inserted marker genes (GFP) as illustrated in this study.
Fluorescent imaging can assist clinicians by detecting viral distribution in order to monitor therapeutic effects via tumor localization and drug toxicity. Our laboratory has previously shown that this viral reporter gene may be utilized as a predictor of response to therapy [10] and to monitor invasion and metastatic spread in TNBC cells [11] . Lastly, we note that oncolytic vaccinia therapy is a safe approach as it has been demonstrated to be safely given to millions of patients during the smallpox eradication.
In conclusion, this is the first study to show the therapeutic efficacy of a novel virus, GLV-1h164 carrying an anti-angiogenic scAb (GLAF-2) in vitro and in a xenograft mammary fat pad model. Specifically, we demonstrate significantly enhanced regression of tumor volumes and decreased angiogenesis with ultrasound imaging after a single injection of GLV-1h164 compared to its parent virus in vivo. Altogether, the VACV-mediated delivery and production of a therapeutic anti-VEGF scAb in colonized tumors may offer a tumor-specific, locally amplified drug therapy for patients with TNBC.
